University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada.
Dermatrials Research Inc. & Venderm Innovations in Psoriasis, Hamilton, ON, Canada.
Skin Therapy Lett. 2021 May;26(3):1-4.
Psoriasis is an immune-mediated inflammatory skin disease that affects about 2% of the population and is associated with many comorbidities. Recent advances have demonstrated interleukin (IL)-17 signaling plays a crucial role in the pathogenesis of psoriasis. Bimekizumab is a novel monoclonal antibody treatment for psoriasis that uses a single binding site to inhibit IL-17A and IL-17F. Here we will discuss the safety and efficacy of bimekizumab in the treatment of moderate-to-severe plaque psoriasis.
银屑病是一种免疫介导的炎症性皮肤病，影响约 2%的人口，并与许多合并症相关。最近的进展表明白细胞介素（IL）-17 信号在银屑病的发病机制中起着关键作用。Bimekizumab 是一种新型的治疗银屑病的单克隆抗体药物，它使用单个结合位点来抑制 IL-17A 和 IL-17F。在这里，我们将讨论 bimekizumab 在治疗中重度斑块状银屑病中的安全性和疗效。
